Common Stock, par value $0.001
- Symbol
- EYPT
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
EyePoint, Inc.
EYPTNASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On September 10, 2026, EyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Company context
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with EyePoint’s proprietary bioerodible Durasert E™ sustained-delivery technology. DURAVYU is currently being evaluated in Phase 3 pivotal trials for diabetic macular edema (DME).
Current securities
Recent company filings
- SCHEDULE 13G - filed by TANG CAPITAL MANAGEMENT LLC regarding EyePoint, Inc.Oct 27, 2026
- Results of Operations and Financial Condition · Costs Associated with Exit or Disposal Activities · Other EventsOct 19, 2026
- Other EventsOct 19, 2026
- SCHEDULE 13G/A - filed by FEDERATED HERMES, INC. regarding EyePoint, Inc.Oct 7, 2026
- 4 filingAug 18, 2026
Registered securities in this filing
EyePoint, Inc. · 8-K · Filed 2026-09-10
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 10, 2026, EyePoint, Inc. posted an updated investor presentation on its website at www.eyepoint.bio. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Filed exhibits (1)
EX-99.1 2 eypt-ex99_1.htm EX-99.1 LUGANO Phase 3 Clinical Trial DURAVYU in Wet AMD Expanded Results & Analyses | September 2026 Exhibit 99.1 Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, are forward-looking statements, including but not limited to statements regarding: our expectations regarding our clinical development and regulatory plans, including the submission of a potential FDA New Drug Application for DURAVYU™ for the potential treatment of wet AMD in the first half of 2027; our confidence in DURAVYU as a potential treatment for wet AMD; our belief that DURAVYU is well positioned to be a potentially practice-changing product and potentially the first-to-market among all investigational sustained release treatments for the two largest retinal disease markets, wet AMD and DME; our belief that DURAVYU is the only TKI in development for DME;…
Open exhibit ↗